Levetiracetam
Product Images NDC 17856-0241

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 17856-0241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corps., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (17856 0241 03label)

Label for Levetiracetam oral solution 1500 mg per 15 mL by Atlantic Biologicals Corps. The label includes dosage instructions (15 mL unit dose cup), storage conditions, manufacturer information (Hi-Tech Pharmacal Co., Inc.), repackager and distributor details, and a contact number for questions. It also features a barcode and NDC 17856-0241-03.*

FDA Label Image

Image Description (Image 01)

Chemical structure diagram of Levetiracetam, showing a 2-oxopyrrolidine ring with ethyl and carbamoylmethyl substituents as depicted in the molecular formula illustration.*

FDA Label Image

Image Description (Image 02)

A bar graph showing the percentage of patients in three different groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The y-axis represents the percentage of patients, with values ranging from 0% to 45%. Each bar includes the sample size (N) for each group and indicates statistical significance with an asterisk for the Levetiracetam groups.*

FDA Label Image

Image Description (Image 03)

A bar graph comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis represents the percentage of patients, showing an increase from placebo to higher dosages of Levetiracetam. Sample sizes for each group are indicated below the x-axis labels.*

FDA Label Image

Image Description (Image 04)

A bar chart comparing the percentage of patients for two groups: Placebo with 104 participants showing 14.4%, and Levetiracetam 3000 mg/day with 180 participants showing 39.4%. The y-axis represents the percentage of patients.*

FDA Label Image

Image Description (Image 05)

Bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The placebo group (N=97) shows about 19.6% of patients, while the Levetiracetam group (N=101) shows about 44.6% of patients. The vertical axis represents the percentage of patients.*

FDA Label Image

Image Description (Image 06)

A bar graph comparing the percentage of patients responding to Placebo versus Levetiracetam treatment. The y-axis shows the percentage of patients from 0% to 100%, with the Placebo group at 45.2% (N=84) and the Levetiracetam group at 72.2% (N=79).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.